EpiCor® Reduces Allergy Symptoms

ANKENY, IowaResults from a new study published in Advances in Therapy (2009:26(8):795-804) found EpiCor®, from Embria Health, significantly reduced the severity of allergy symptoms. The randomized, double blind, placebo-controlled study gave 96 healthy test subjects with recent history of seasonal allergies and allergic rhinitis (AR) 500 mg/d of EpiCor or a placebo over a 12-week period of the highest recorded concentrations of total pollen counts for the Midwest geographic area. Results were measured with in-clinic examinations, validated questionnaires and diaries and serologic analysis at baseline, six and 12 weeks. The study found that EpiCor significantly reduced the severity of specific AR symptoms, including nasal congestion and rhinorrhea (runny nose).

"When out of balance, the immune system fails to protect the body. An over-stimulated immune system may result in allergies by mistaking harmless environmental substances such as pollen for an attacking parasite," explaind Larry Robinson, Ph.D., vice president of scientific affairs for Embria Health Sciences and one of the study's primary researchers. "EpiCor works to keep the immune system at a balanced state so that it can properly respond to pollen and allergens."